PDC Biotech completes phase I clinical trial of PDC31

The trial was designed to evaluate safety and also to provide proof-of-concept for the ability of the compound to inhibit excessive uterine contractility.

During the study the healthy women with primary dysmenorrhea were administered with PDC31, which led to pain relief as well as a reduction in intrauterine pressure.

The study also reported the well toleration of PDC31 inspite of no dose limitations.

PDC managing director Roman Götz said, "We are pleased with the encouraging results of this study, which now enable us to move forward into further development for the preterm labour indication."

PDC board chairman Ernest Loumaye said, "The first administration in human study is an important step toward the development of this first in class compound, as the compound is well tolerated and pharmacodynamic results provide preliminary evidence in man of the validity of the target for the selected indications."

PDC31 is a synthetic octapeptide designed to act as an allosteric modulator of the receptor for prostaglandin F2a (FP receptor).